DUBLIN, July 28, 2011 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces results for the three months to June 30, 2011. Financial Highlights Q2 2011(1) Product sales
DUBLIN, July 28, 2011 /PRNewswire/ Shire plc , the global specialty biopharmaceutical company, announces results for the three months to June 30, 2011. Financial Highlights Q2 2011(1) Product sales $993 million +30% Total revenues $1,063 …
Impax Laboratories Inc. said Tuesday its second-quarter earnings sank 60 percent compared to last year's quarter, when the drugmaker had marketing exclusivity to sell a generic version of the enlarged prostate treatment Flomax.
HAYWARD, Calif.--(BUSINESS WIRE)--Impax Laboratories, Inc. (NASDAQ: IPXL) today reported second quarter ended June 30, 2011 financial results. “Our second quarter 2011 revenues and earnings were lower than the prior year period primarily due to higher s
Impax Laboratories Inc. Posted on:02 Aug 11 Impax Laboratories, Inc. (NASDAQ: IPXL) today reported second quarter ended June 30, 2011 financial results.